British Journal of Nutrition

Full Papers

New insights into the impact of the intestinal microbiota on health and disease: a symposium report

Linda V. Thomasa1 c1 and Theo Ockhuizena2

a1 Yakult UK Limited, Odyssey Business Park, West End Road, South Ruislip, Mddx HA4 6QE, UK

a2 Nutricom Consultancy, Dorpsdijk, 10, 4156 AK Rumpt, The Netherlands


The present report summarises key insights from a recent symposium focusing on the impact of the intestinal microbiota on health and disease. A more appropriate definition of health was proposed since health maintenance is a dynamic process better assessed in terms of ability to adapt to stress and maintain physiological homeostasis. Biomarkers specifically for health are needed; use of challenge models and subjects with suboptimal health or specific disease risk were advised. The complexity of interactions between external factors, the intestinal epithelium, intestinal microbiota, the immune system and health was exemplified by describing the effects of antibiotics, the Western diet and non-digestible carbohydrates on the microbiota. The association of certain bacteria with different states of health or disease was acknowledged but also that is not always clear whether this is a cause or effect. Recent identification of three robust faecal metagenome clusters may advance this understanding. It was speculated that knowledge of the intestinal microbiota profile may eventually help in the diagnosis of health risks and choice of therapy. It was agreed that beneficial manipulation of the commensal microbiota can improve health outcome. For this purpose, three areas were reviewed. Firstly, research into probiotics as vaccine adjuvants was considered useful for substantiation of immune function claims. Secondly, positive results with certain probiotics and synbiotics for colorectal cancer are emerging, mostly from in vitro and animal studies. Finally, studies in endurance athletes have shown strain-specific probiotic benefit in terms of maintenance of immune function and, for certain strains, reduction of episodes of respiratory and/or gastrointestinal tract infections.

(Received September 07 2011)

(Revised October 21 2011)

(Accepted November 16 2011)


c1 Corresponding author: L. V. Thomas, fax +44 20 8839 3250, email

Abbreviations: CRC, colorectal cancer; IBS, irritable bowel syndrome; Treg, regulatory T; URTI, upper respiratory tract infections